Total Payments
$24,976
2024 Payments
$16,346
Companies
25
Transactions
117
Medicare Patients
1,482
Medicare Billing
$268,561
Payment Breakdown by Category
Consulting$11,218 (44.9%)
Other$9,000 (36.0%)
Food & Beverage$3,350 (13.4%)
Travel$1,211 (4.8%)
Education$197.65 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $11,218 | 4 | 44.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $9,000 | 9 | 36.0% |
| Food and Beverage | $3,350 | 93 | 13.4% |
| Travel and Lodging | $1,211 | 8 | 4.8% |
| Education | $197.65 | 3 | 0.8% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $18,795 | 49 | $0 (2024) |
| E.R. Squibb & Sons, L.L.C. | $4,237 | 10 | $0 (2024) |
| Incyte Corporation | $267.34 | 8 | $0 (2024) |
| Daiichi Sankyo Inc. | $259.29 | 8 | $0 (2024) |
| Genentech USA, Inc. | $245.96 | 2 | $0 (2023) |
| Gilead Sciences, Inc. | $217.24 | 7 | $0 (2024) |
| Ipsen Biopharmaceuticals, Inc | $124.21 | 1 | $0 (2018) |
| Janssen Biotech, Inc. | $89.38 | 2 | $0 (2024) |
| ABBVIE INC. | $80.14 | 3 | $0 (2024) |
| Lilly USA, LLC | $68.82 | 3 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $16,346 | 71 | AstraZeneca Pharmaceuticals LP ($13,297) |
| 2023 | $7,988 | 37 | AstraZeneca Pharmaceuticals LP ($5,377) |
| 2022 | $444.20 | 7 | Genentech USA, Inc. ($125.41) |
| 2018 | $198.16 | 2 | Ipsen Biopharmaceuticals, Inc ($124.21) |
All Payment Transactions
117 individual payment records from CMS Open Payments — Page 1 of 5
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $3.82 | General |
| Category: Oncology | ||||||
| 12/16/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $34.03 | General |
| Category: Oncology | ||||||
| 12/09/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $113.50 | General |
| 12/04/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $31.66 | General |
| Category: Oncology | ||||||
| 11/28/2024 | Takeda Pharmaceuticals U.S.A., Inc. | ALUNBRIG (Drug) | Food and Beverage | In-kind items and services | $34.40 | General |
| Category: ONCOLOGY | ||||||
| 11/18/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $33.95 | General |
| Category: Oncology | ||||||
| 11/13/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $25.23 | General |
| Category: ONCOLOGY | ||||||
| 11/12/2024 | Incyte Corporation | JAKAFI (Drug), MONJUVI | Food and Beverage | Cash or cash equivalent | $22.54 | General |
| Category: Hematology/Oncology | ||||||
| 11/05/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $31.48 | General |
| Category: Oncology | ||||||
| 11/01/2024 | Gilead Sciences, Inc. | Trodelvy (Drug) | Food and Beverage | In-kind items and services | $33.44 | General |
| Category: ONC | ||||||
| 10/24/2024 | E.R. Squibb & Sons, L.L.C. | OPDIVO (Biological) | Food and Beverage | Cash or cash equivalent | $28.95 | General |
| Category: Oncology | ||||||
| 10/23/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $34.50 | General |
| Category: Oncology | ||||||
| 10/15/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $19.66 | General |
| Category: ONCOLOGY | ||||||
| 10/14/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $23.72 | General |
| Category: ONCOLOGY | ||||||
| 10/10/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $13.95 | General |
| 10/08/2024 | Incyte Corporation | MONJUVI (Drug), JAKAFI, PEMAZYRE | Food and Beverage | Cash or cash equivalent | $26.74 | General |
| Category: Oncology | ||||||
| 09/25/2024 | AstraZeneca Pharmaceuticals LP | ENHERTU (Biological) | Food and Beverage | In-kind items and services | $34.55 | General |
| Category: Oncology | ||||||
| 09/24/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: Oncology | ||||||
| 09/17/2024 | Incyte Corporation | JAKAFI (Drug), PEMAZYRE, MONJUVI | Food and Beverage | Cash or cash equivalent | $24.94 | General |
| Category: Hematology/Oncology | ||||||
| 09/17/2024 | GlaxoSmithKline, LLC. | JEMPERLI (Biological) | Food and Beverage | In-kind items and services | $23.34 | General |
| Category: ONCOLOGY | ||||||
| 09/10/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Food and Beverage | In-kind items and services | $28.17 | General |
| Category: Oncology | ||||||
| 08/28/2024 | Daiichi Sankyo Inc. | Enhertu (Drug) | Food and Beverage | In-kind items and services | $26.15 | General |
| Category: ONCOLOGY | ||||||
| 08/26/2024 | Celgene Corporation | REBLOZYL (Biological) | Food and Beverage | Cash or cash equivalent | $21.09 | General |
| Category: Hematology | ||||||
| 08/24/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $30.17 | General |
| 08/23/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,200.00 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 475 | 750 | $244,150 | $89,861 |
| 2022 | 7 | 404 | 604 | $177,300 | $63,250 |
| 2021 | 10 | 533 | 839 | $260,705 | $102,763 |
| 2020 | 5 | 70 | 100 | $31,289 | $12,687 |
Total Patients
1,482
Total Services
2,293
Medicare Billing
$268,561
Procedure Codes
28
All Medicare Procedures & Services
28 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 187 | 350 | $95,840 | $34,872 | 36.4% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 94 | 196 | $74,993 | $27,949 | 37.3% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 89 | 89 | $41,894 | $15,682 | 37.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 38 | 38 | $13,554 | $4,794 | 35.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 51 | 60 | $11,630 | $4,063 | 34.9% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 16 | 17 | $6,239 | $2,503 | 40.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 152 | 286 | $77,825 | $28,009 | 36.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 48 | 82 | $31,184 | $12,366 | 39.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $19,176 | $7,627 | 39.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 99 | 125 | $24,294 | $6,451 | 26.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $11,439 | $3,795 | 33.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 20 | 22 | $9,014 | $3,696 | 41.0% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 12 | 16 | $4,368 | $1,306 | 29.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 186 | 313 | $84,668 | $33,166 | 39.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 112 | 219 | $82,548 | $33,042 | 40.0% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 88 | 88 | $31,864 | $12,023 | 37.7% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Office | 2021 | 36 | 36 | $17,048 | $6,724 | 39.4% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 13 | 41 | $10,752 | $4,598 | 42.8% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 19 | 22 | $9,427 | $3,648 | 38.7% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 14 | 40 | $8,884 | $3,465 | 39.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 36 | 37 | $7,219 | $2,775 | 38.4% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 31 | $4,791 | $1,917 | 40.0% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 11 | 12 | $3,504 | $1,407 | 40.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 11 | 37 | $8,288 | $3,374 | 40.7% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Office | 2020 | 16 | 16 | $7,216 | $2,931 | 40.6% |
About Dr. Zhuoyan Li, MD
Dr. Zhuoyan Li, MD is a Hematology & Oncology healthcare provider based in Baltimore, Maryland. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/28/2014. The National Provider Identifier (NPI) number assigned to this provider is 1619387867.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Zhuoyan Li, MD has received a total of $24,976 in payments from pharmaceutical and medical device companies, with $16,346 received in 2024. These payments were reported across 117 transactions from 25 companies. The most common payment nature is "Consulting Fee" ($11,218).
As a Medicare-enrolled provider, Li has provided services to 1,482 Medicare beneficiaries, totaling 2,293 services with total Medicare billing of $268,561. Data is available for 4 years (2020–2023), covering 28 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Baltimore, MD
- Active Since 04/28/2014
- Last Updated 03/08/2023
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1619387867
Products in Payments
- CALQUENCE (Drug) $18,210
- OPDIVO (Biological) $167.82
- Trodelvy (Drug) $143.14
- Enhertu (Drug) $139.59
- MONJUVI (Drug) $127.97
- Perjeta (Biological) $125.41
- Onivyde (Drug) $124.21
- Phesgo (Biological) $120.55
- ENHERTU (Drug) $119.70
- ENHERTU (Biological) $106.35
- VENCLEXTA (Drug) $80.14
- IMBRUVICA (Drug) $73.95
- JAKAFI (Drug) $73.21
- ULTOMIRIS (Biological) $61.05
- LONSURF (Drug) $57.56
- KEYTRUDA (Biological) $53.26
- MONOFERRIC (Drug) $52.71
- LIBTAYO (Biological) $49.03
- VERZENIO (Drug) $46.90
- REBLOZYL (Biological) $43.42
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Baltimore
Miss. Ani Balmanoukian, M.d, M.D
Hematology & Oncology — Payments: $842,199
Hematology & Oncology $842,199
Dr. Benjamin Levy, Md, MD
Hematology & Oncology — Payments: $814,882
Hematology & Oncology $814,882
Dr. Patrick Forde, M.d, M.D
Hematology & Oncology — Payments: $253,665
Hematology & Oncology $253,665
Josephine Feliciano, M.d, M.D
Hematology & Oncology — Payments: $125,936
Hematology & Oncology $125,936
Djordje Atanackovic, M.d, M.D
Hematology & Oncology — Payments: $117,434
Hematology & Oncology $117,434
Huzefa Bahrain, D.o, D.O
Hematology & Oncology — Payments: $103,816
Hematology & Oncology $103,816